AsthmaPhase 1EndomacNCT00839124
A Study of Inhalation of 20,000 EU CCRE in Normal Volunteers Compared to Allergic Asthmatic Individuals
A Phase 1 study testing Clinical Center Reference Endotoxin (CCRE) in people with Asthma and Hypersensitivity, run by University of North Carolina, Chapel Hill at 1 site in United States.
Trial summary
This will be a single center, open label study comparing baseline characteristics of recovered sputum cells (collected on screening day) to those of cells recovered 6 hours after inhalational challenge with 20,000 EU Clinical Center Reference Endotoxin (CCRE, a component of air pollution)) within each group as well as… Read more about this study
- Who is it for?
- Ages 18 to 50 yearsHealthy volunteers can take part
- Conditions the study is for
- Asthma, Hypersensitivity
- What is being tested?
- Clinical Center Reference Endotoxin (CCRE)
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 32 participants
- Where
- 1 siteUnited States
- Study dates
- Jan 2009to Sep 2012
- Phase
- Phase 1
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 50 years
- All sexes
- Healthy volunteers accepted
- Adult
Who may be able to join
- Normal lung function, defined as (Knudson 1976/1984 predicted set):
- FVC of > 80 % of that predicted for gender, ethnicity, age and height FEV1 of > 80 % of that predicted for gender, ethnicity, age and height FEV1/FVC ratio of > .75
- Oxygen saturation of > 94 % and normal blood pressure (Systolic between 150 - 90, Diastolic between 90-60 mm Hg)
- Symptom Score no greater than 6 (out of a possible 24) for total symptom score with a value no greater than 2 for any one score.
- Negative methacholine inhalation challenge as performed in the screening protocol. (Less than a 20% decrease in FEV1 at a maximum methacholine concentration of 10 mg/ml)
- --Negative pregnancy test for females
Show all 12Show fewer
- Negative allergy skin test (AST)
- History of episodic wheezing, chest tightness, or shortness of breath after age of 6 years consistent with asthma, or physician diagnosed asthma after age of 6 years.
- Positive methacholine test.
- FEV1 of at least 80% of predicted and FEV1/FVC ratio of at least .70 (without use of bronchodilating medications for 12 hours)
- Allergic sensitization to at least one of the following allergen preparations: (House Dust Mite f, House dust mite p, Cockroach, Tree mix, Grass Mix, Weed Mix, Mold Mix 1, Mold Mix 2, Rat, Mouse, Guinea Pig, Rabbit, Cat or Dog) confirmed by positive AST.
- Negative allergy skin test as performed in the screening protocol.
Who cannot join
- Any chronic medical condition considered by the PI as a contraindication to the exposure study including significant cardiovascular disease, diabetes requiring medication, chronic renal disease, or chronic thyroid disease.
- Physician directed emergency treatment for an asthma exacerbation within the preceding 12 months.
- Use of systemic steroid therapy within the preceding 12 months for an asthma exacerbation. All use of systemic steroids in the last year will be reviewed by a study physician.
- Use of inhaled steroids, cromolyn or leukotriene inhibitors (montelukast or zafirlukast) except for use of cromolyn exclusively prior to exercise.
- Use of daily theophylline within the past month.
- Use of tricyclics and MAO inhibitors
Show all 14Show fewer
- Pregnancy or nursing a baby.
- Cigarette smoking > 1 pack per month.
- Nighttime symptoms of cough or wheeze greater than 1x/week at baseline (not during a clearly recognized viral induced asthma exacerbation) which would be characteristic of a person of moderate or severe persistent asthma as outlined in the current NHLBI guidelines for diagnosis and management of asthma.
- Exacerbation of asthma more than 2x/week which would be characteristic of a person of moderate or severe persistent asthma as outlined in the current NHLBI guidelines for diagnosis and management of asthma.
- Daily requirement for albuterol due to asthma symptoms (cough, wheeze, chest tightness) which would be characteristic of a person of moderate or severe persistent asthma as outlined in the current NHLBI guidelines for diagnosis and management of asthma. (Not to include prophylactic use of albuterol prior to exercise).
- Viral upper respiratory tract infection within 2 weeks of challenge.
- Any acute infection requiring antibiotics within 2 weeks of challenge
- Receipt of LAIV (Live Attenuated Influenza Vaccine), also know as FluMist®, within the prior 14 days
Trial locations and contacts
1 site in 1 country.
United States1 site
UNC Center for Environmental Medicine, Asthma and Lung Biology
Chapel Hill, North Carolina, 27599-7310
About this study
Official title: A Study of Inhalation of 20,000 EU Clinical Center Reference Endotoxin in Normal Volunteers Compared to Allergic Asthmatic Individuals
This will be a single center, open label study comparing baseline characteristics of recovered sputum cells (collected on screening day) to those of cells recovered 6 hours after inhalational challenge with 20,000 EU Clinical Center Reference Endotoxin (CCRE, a component of air pollution)) within each group as well as cross group comparisons between individuals with allergic asthma (AA's)and normal volunteers (NV's). The primary objective of this study is to test the hypothesis that persons with allergic asthma will have an increased neutrophil response to challenge with 20,000 EU CCRE compared to normal volunteers. Secondary objectives include post CCRE comparison between AA's and NV's with regard to changes in airway cells and blood as well as changes in mucociliary clearance (MCC) in response to inhalation of 20,000 EU CCRE.
Read the detailed description
This will be a single center, open label study of allergic asthmatic and normal volunteers. The protocol will compare baseline characteristics of recovered sputum cells (collected on screening day) to those of cells recovered 6 hours after inhalational challenge with CCRE within each group as well as cross group comparisons between AA's and NV's. The following information indicates procedures to be performed at each visit as well as the anticipated duration of visits. Subsequent to this description are details regarding specific study procedures.
Visit 1: Baseline Visit (5 hours)
- Consent will be obtained, review of subject's medical history, current medications and inclusion/exclusion criteria.
- Vital sign measurements (temperature, pulse, respiratory rate, blood pressure), oxygen saturation, and symptom scoring
- Urine pregnancy test for women of child bearing potential
- Spirometry
- Venipuncture for CBC with differential and baseline blood analyses
- Physical exam of the ears, nose, throat and chest
- Collection of exhaled breath for measurement of nitric oxide level
- Xenon equilibrium gas scan and MCC
- MCC scan
- Sputum induction
- After completion of the sputum induction, subjects will have brief MCC scan (< 10 minutes)
Visit 2: 24 hours post baseline subjects will return for the following 1 hour visit:
- Review any change in medical status over prior 24 hours, vital signs, O2 saturation and symptom score
- Follow up MCC scan
Visit 3: 24-48 hours prior to challenge visit at least 2 days after the baseline visit (½ hour)
- Review change in medical status since last visit; vital signs, oxygen saturation, \& symptom score
- Urine pregnancy test
- Spirometry
Visit 4: Endotoxin (CCRE) challenge day (8.5 to 9 hours)
- Review any change in medical status since last visit
- Vital signs, oxygen saturation, and symptom score
- Spirometry
- Physical exam of the ears, nose, throat and chest
- If above measures are acceptable, CCRE challenge will be performed
- Post-challenge monitoring including spirometry, vital signs, oxygen saturation, and symptom score at the following intervals post challenge: 30 and 60 minutes and then hourly for 5 additional hours.
- Post challenge venipuncture (blood draw) for CBC with differential and post CCRE blood analyses
- Collection of exhaled breath for measurement of nitric oxide level.
- Four hours post challenge, subject will have MCC evaluated
- After MCC is assessed, sputum induction will be performed.
- After completion of the sputum induction, subjects will have brief MCC scan (< 10 minutes)
- Discharge home or, alternatively, to GCRC for overnight observation per study MD.
Visit 5: 24 hours post challenge visit (1 hour)
- Subject returns to the CEMALB, vital signs, oxygen saturation, and symptom score
- Collection of exhaled breath for measurement of nitric oxide level.
- Spirometry
- Follow-up MCC scan
- Each volunteer will be given a symptom scoring sheet for each day up to 96 hours (4 days) after challenge (see accompanying symptom scoring sheet in Appendix 3).
Post Challenge Observations/Reporting (5 minutes)
- Subjects will be contacted for phone call follow-up 48-96 hours after challenge (see script Appendix 4 of accompanying protocol)
Study discontinuation visit within 10 days of the challenge dose: (15 minutes)
- Vital signs, O2 saturation, symptom score, spirometry
- If any findings are abnormal, medical evaluation as directed by the study physician will be undertaken Appendix 1 of the accompanying protocol provides a summary table regarding procedures performed at each subject study visit
- Conditions
- Asthma, Hypersensitivity
- Being tested
- Clinical Center Reference Endotoxin (CCRE)
- Keywords
- normal volunteer, healthy control volunteer, healthy subjects, asthma, allergy, allergic asthma
- Medical subject headings
- Asthma, Hypersensitivity
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Clinical Center Reference Endotoxin (CCRE)Biological
Also called air pollution
inhalation challenge with 20,000 EU CCRE
Clinical Center Reference Endotoxin (CCRE)Biological
Also called air pollution
inhalation of 20,000 EU CCRE
| Study group | Role | What they receive |
|---|---|---|
| Allergic asthma | Active comparator | subjects with allergic asthma will undergo challenge with 20,000 EU CCRE Receives: Biological: Clinical Center Reference Endotoxin (CCRE) |
| healthy control | Active comparator | Healthy volunteers will undergo challenge with 20,000 EU CCRE Receives: Biological: Clinical Center Reference Endotoxin (CCRE) |
What is being measured
The primary outcome is the main question the study is designed to answer.
The primary objective of this study is to test the hypothesis that persons with allergic asthma will have an increased neutrophil response to challenge with 20,000 EU CCRE compared to normal volunteers
Measured: 6 hours post challenge
Secondary outcomes (1)
Secondary objectives include post CCRE comparison between AA's and NV's with regard to changes in airway cells and blood as well as changes in mucociliary clearance (MCC) in response to inhalation of 20,000 EU CCRE.
Measured: 6-24 hours post challenge
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted9 Feb 2009 (estimated)
- Study startJan 2009
- Primary completionSep 2012
- Study completionSep 2012
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (2)Papers the sponsor has linked to this study.
- Other trials for AsthmaStudies of the same condition, open and under way.
- More trials run by University of North Carolina, Chapel HillThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 1
- Primary purpose
- Basic science
- Allocation
- Non-randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Enrolment
- 32 participants (actual)
Sponsor and investigators
- Lead sponsor
- University of North Carolina, Chapel Hill
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
- Investigators
- David B Peden, MD, MS, Principal investigator, University of North Carolina at Chapel Hill, Dept of Pediatrics / Center for Environmental Medicine, Asthma and Lung Biology
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT00839124
- Sponsor's protocol ID
- 08-1750 (CTRC # 2776)
- Other IDs
- 5U19AI077437-02
- Acronym
- Endomac
- Status last verified
- Dec 2012
- First submitted
- 6 Feb 2009
- Last updated
- 5 Dec 2012
- Results posted
- No
- Data monitoring committee
- Yes
Publications
Bennett WD, Alexis NE, Almond M, Herbst M, Zeman KL, Peden DB. Effect of inhaled endotoxin on mucociliary clearance and airway inflammation in mild smokers and nonsmokers. J Aerosol Med Pulm Drug Deliv. 2014 Dec;27(6):459-65. doi: 10.1089/jamp.2013.1089.
PubMed 24568613Bennett WD, Herbst M, Zeman KL, Wu J, Hernandez ML, Peden DB. Effect of inhaled endotoxin on regional particle deposition in patients with mild asthma. J Allergy Clin Immunol. 2013 Mar;131(3):912-3. doi: 10.1016/j.jaci.2012.09.010. Epub 2012 Oct 25. No abstract available.
PubMed 23102735
Study at a glance
From the registry record, last updated by the sponsor on 5 Dec 2012. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- A Study of Inhalation of 20,000 EU Clinical Center Reference Endotoxin in Normal Volunteers Compared to Allergic Asthmatic Individuals
- ClinicalTrials.gov ID
- NCT00839124
- Acronym / sponsor ID
- Endomac / 08-1750 (CTRC # 2776)
- Conditions
- Asthma, Hypersensitivity
- Keywords
- normal volunteer, healthy control volunteer, healthy subjects, asthma, allergy, allergic asthma
- Phase
- Phase 1
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 32 participants (actual)
- Lead sponsor
- University of North Carolina, Chapel HillUniversity, hospital or other
- Collaborators
- National Institute of Allergy and Infectious Diseases (NIAID)
- Study start
- Jan 2009
- Primary completion
- Sep 2012 (actual)
- Study completion
- Sep 2012 (actual)
- First posted
- 9 Feb 2009 (estimated)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This will be a single center, open label study comparing baseline characteristics of recovered sputum cells (collected on screening day) to those of cells recovered 6 hours after inhalational challenge with 20,000 EU Clinical Center Reference Endotoxin (CCRE, a component of air pollution)) within each group as well as cross group comparisons between individuals with allergic asthma (AA's)and normal volunteers (NV's). The primary objective of this study is to test the hypothesis that persons with allergic asthma will have an increased neutrophil response to challenge with 20,000 EU CCRE compared to normal volunteers. Secondary objectives include post CCRE comparison between AA's and NV's with regard to changes in airway cells and blood as well as changes in mucociliary clearance (MCC) in response to inhalation of 20,000 EU CCRE.
Detailed description
This will be a single center, open label study of allergic asthmatic and normal volunteers. The protocol will compare baseline characteristics of recovered sputum cells (collected on screening day) to those of cells recovered 6 hours after inhalational challenge with CCRE within each group as well as cross group comparisons between AA's and NV's. The following information indicates procedures to be performed at each visit as well as the anticipated duration of visits. Subsequent to this description are details regarding specific study procedures.
Visit 1: Baseline Visit (5 hours)
- Consent will be obtained, review of subject's medical history, current medications and inclusion/exclusion criteria.
- Vital sign measurements (temperature, pulse, respiratory rate, blood pressure), oxygen saturation, and symptom scoring
- Urine pregnancy test for women of child bearing potential
- Spirometry
- Venipuncture for CBC with differential and baseline blood analyses
- Physical exam of the ears, nose, throat and chest
- Collection of exhaled breath for measurement of nitric oxide level
- Xenon equilibrium gas scan and MCC
- MCC scan
- Sputum induction
- After completion of the sputum induction, subjects will have brief MCC scan (< 10 minutes)
Visit 2: 24 hours post baseline subjects will return for the following 1 hour visit:
- Review any change in medical status over prior 24 hours, vital signs, O2 saturation and symptom score
- Follow up MCC scan
Visit 3: 24-48 hours prior to challenge visit at least 2 days after the baseline visit (½ hour)
- Review change in medical status since last visit; vital signs, oxygen saturation, \& symptom score
- Urine pregnancy test
- Spirometry
Visit 4: Endotoxin (CCRE) challenge day (8.5 to 9 hours)
- Review any change in medical status since last visit
- Vital signs, oxygen saturation, and symptom score
- Spirometry
- Physical exam of the ears, nose, throat and chest
- If above measures are acceptable, CCRE challenge will be performed
- Post-challenge monitoring including spirometry, vital signs, oxygen saturation, and symptom score at the following intervals post challenge: 30 and 60 minutes and then hourly for 5 additional hours.
- Post challenge venipuncture (blood draw) for CBC with differential and post CCRE blood analyses
- Collection of exhaled breath for measurement of nitric oxide level.
- Four hours post challenge, subject will have MCC evaluated
- After MCC is assessed, sputum induction will be performed.
- After completion of the sputum induction, subjects will have brief MCC scan (< 10 minutes)
- Discharge home or, alternatively, to GCRC for overnight observation per study MD.
Visit 5: 24 hours post challenge visit (1 hour)
- Subject returns to the CEMALB, vital signs, oxygen saturation, and symptom score
- Collection of exhaled breath for measurement of nitric oxide level.
- Spirometry
- Follow-up MCC scan
- Each volunteer will be given a symptom scoring sheet for each day up to 96 hours (4 days) after challenge (see accompanying symptom scoring sheet in Appendix 3).
Post Challenge Observations/Reporting (5 minutes)
- Subjects will be contacted for phone call follow-up 48-96 hours after challenge (see script Appendix 4 of accompanying protocol)
Study discontinuation visit within 10 days of the challenge dose: (15 minutes)
- Vital signs, O2 saturation, symptom score, spirometry
- If any findings are abnormal, medical evaluation as directed by the study physician will be undertaken Appendix 1 of the accompanying protocol provides a summary table regarding procedures performed at each subject study visit
Study design
- Primary purpose
- Basic science
- Allocation
- Non-randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Allergic asthma | Active comparator | Biological: Clinical Center Reference Endotoxin (CCRE)subjects with allergic asthma will undergo challenge with 20,000 EU CCRE |
| healthy control | Active comparator | Biological: Clinical Center Reference Endotoxin (CCRE)Healthy volunteers will undergo challenge with 20,000 EU CCRE |
Who may qualify
- Ages
- 18 to 50 years
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult
Key inclusion criteria (12 listed)
- Normal lung function, defined as (Knudson 1976/1984 predicted set):
- FVC of > 80 % of that predicted for gender, ethnicity, age and height FEV1 of > 80 % of that predicted for gender, ethnicity, age and height FEV1/FVC ratio of > .75
- Oxygen saturation of > 94 % and normal blood pressure (Systolic between 150 - 90, Diastolic between 90-60 mm Hg)
- Symptom Score no greater than 6 (out of a possible 24) for total symptom score with a value no greater than 2 for any one score.
- Negative methacholine inhalation challenge as performed in the screening protocol. (Less than a 20% decrease in FEV1 at a maximum methacholine concentration of 10 mg/ml)
Key exclusion criteria (14 listed)
- Any chronic medical condition considered by the PI as a contraindication to the exposure study including significant cardiovascular disease, diabetes requiring medication, chronic renal disease, or chronic thyroid disease.
- Physician directed emergency treatment for an asthma exacerbation within the preceding 12 months.
- Use of systemic steroid therapy within the preceding 12 months for an asthma exacerbation. All use of systemic steroids in the last year will be reviewed by a study physician.
- Use of inhaled steroids, cromolyn or leukotriene inhibitors (montelukast or zafirlukast) except for use of cromolyn exclusively prior to exercise.
- Use of daily theophylline within the past month.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Clinical Center Reference Endotoxin (CCRE)Also: air pollutioninhalation challenge with 20,000 EU CCRE | Biological | healthy control |
| Clinical Center Reference Endotoxin (CCRE)Also: air pollutioninhalation of 20,000 EU CCRE | Biological | Allergic asthma |
Primary outcome
The primary objective of this study is to test the hypothesis that persons with allergic asthma will have an increased neutrophil response to challenge with 20,000 EU CCRE compared to normal volunteers
Time frame: 6 hours post challenge
1 secondary outcome
Secondary objectives include post CCRE comparison between AA's and NV's with regard to changes in airway cells and blood as well as changes in mucociliary clearance (MCC) in response to inhalation of 20,000 EU CCRE.
Time frame: 6-24 hours post challenge
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 5 Dec 2012.
- Derived from this study: PubMed 24568613Bennett WD, Alexis NE, Almond M, Herbst M, Zeman KL, Peden DB. Effect of inhaled endotoxin on mucociliary clearance and airway inflammation in mild smokers and nonsmokers. J Aerosol Med Pulm Drug Deliv. 2014 Dec;27(6):459-65. doi: 10.1089/jamp.2013.1089.
- Derived from this study: PubMed 23102735Bennett WD, Herbst M, Zeman KL, Wu J, Hernandez ML, Peden DB. Effect of inhaled endotoxin on regional particle deposition in patients with mild asthma. J Allergy Clin Immunol. 2013 Mar;131(3):912-3. doi: 10.1016/j.jaci.2012.09.010. Epub 2012 Oct 25. No abstract available.
Related trials for Asthma
RecruitingPhase 1
Pilot Study to Identify the Mediators and Inflammatory Cell Surface Receptors Involved in Allergic Airway Inflammation
Asthma
Recruiting
THERMotherapy Against Persistent Bacterial LUNG Infections
Lung Diseases, Obstructive, Bronchiectasis
RecruitingPhase 1
A Study to Compare the Relative Potency of Salbutamol Administered Via Metered Dose Inhalers (MDI) Containing Propellants HFA-152a to HFA-134a in Mild Asthmatics Aged 18 to 65 Inclusive
Asthma, Mild Asthma
Active, not recruitingPhase 2/3
Local Antibiotic Delivery for Community Acquired Pneumonia
Community Acquired Pneumonia (CAP)
RecruitingPhase 2
A Study to Learn About the Study Medicine Called PF-07275315 in People With Moderate-To-Severe Asthma
Asthma
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
David B Peden, MD, MS principal investigator
University of North Carolina at Chapel Hill, Dept of Pediatrics / Center for Environmental Medicine, Asthma and Lung Biology
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Phase 1 study testing Clinical Center Reference Endotoxin (CCRE) in people with Asthma and Hypersensitivity, run by University of North Carolina, Chapel Hill at 1 site in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 12 inclusion and 14 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 5 Dec 2012. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Phase 1 studies test a treatment in a small group of people for the first time or in a new way, mainly to check safety and find the right dose.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
The primary objective of this study is to test the hypothesis that persons with allergic asthma will have an increased neutrophil response to challenge with 20,000 EU CCRE compared to normal volunteers (time frame: 6 hours post challenge). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT00839124, which also lists 2 linked publications.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 5 Dec 2012; AzTrials last refreshed its copy on 8 Nov 2026.